WEIEASE TECH
HANGZHOU WEIEASE TECH CO.,LTD is an insurance and technology company, dedicated to serving the insurance sector through Internet+ and digitization. The company aspires to “serve society, serve the industry, and serve service agents.” Its innovative insurance APP aims to connect and empower industry-wide agents through better connectivity and more efficient operations. It also serves society by raising awareness on the protection and benefits that can be derived from being insured. After 3+ years of operation, the company is currently one of the largest Internet+ and insurance support platforms nationwide in China.

Early stage investments

YUNGANG HUANG

RUNZE CHEN

RELX Technology
RELX Technology (NYSE:RLX) is a consumer electronic cigarette company founded in China. Its main business is the development, design, and sales of RELX electronic cigarettes. With its advanced technology and product, its mission is to accelerate the transformation of the world’s one billion smokers, and bring to them healthier and happier lifestyles. RELX’s motto is, “Smoking can be delightful and carefree.”​
​RELX (NYSE:RLX) was founded in 2017, and has attracted numerous leading Venture Capital investments from Source Code Capital and IDG Capital. Currently, RELX has offices in Beijing, Shanghai, and Shenzhen, and has plans to expand internationally to better serve its global customer base. RELX’s founding team members come from renowned consumer electronics, FMCG, internet, consulting and investment companies, such as P&G, L'Oreal, Unilever, Huawei, Oppo, Mercedes-Benz, and Bain & Consulting.​

Early stage investments

YUNGANG HUANG

Qing Hotels
Qing Hotels helps the hotel innovation platform in the new era, providing marketing, brand building, operation, hotel talents, supply chain and system empowerment for franchised hotels. It aims to help franchisees, improve operational efficiency and operating income. Since its establishment, it has been stationed in 153 cities, 29 provinces and cities, and more than 2,700 hotels have joined. It has completed three consecutive rounds of funding from top-tier institutions and has emerged as the leader among domestic light franchise hotel chain brands.

Early stage investments

YUNGANG HUANG

JIHONG ZHANG

XYZ Robotics
XYZ Robotics was established in 2018 and is headquartered in Shanghai, China, with an R&D office in Boston, USA. The company's vision is "Pick Anything. Place Anywhere." Explore the boundaries of robotics and provide stable and efficient products. This is the dedicated pursuit of every XYZ-er.

The XYZ Robotics technical team is the only consecutive "Top 3" winner in the Amazon Robotics Challenge, for three consecutive years. With the world's leading deep learning, 3D vision, robot motion planning and other cutting-edge technologies, it provides logistics and manufacturing industries with more efficient, accurate, and easier-to-deploy flexible solutions. This includes small parts sorting, middle part de-stacking, and industrial loading and unloading.

Early stage investments

YUNGANG HUANG

RUNZE CHEN

moody

Early stage investments

YUNGANG HUANG

DANDAN CHEN

METIS
METiS Pharmaceuticals is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas.
By integrating machine learning, quantum simulation, and high-throughput experimentation, we enable scientists to rapidly, comprehensively, and intelligently develop novel drug candidates.

Early stage investments

YUNGANG HUANG

Erin Luo

YIWEN HAO

GALIXIR
Galixir was founded in 2019. We are dedicated to employing cutting-edge artificial intelligence technologies to accelerate drug research and development, to lower development costs, and to quickly bring new drug candidates to clinical stages. Galixir united team members from top multinational pharmaceutical corporations, internet companies, venture capital and consulting firms. Empowering our imagination with wisdom and technology, Galixir strives to find elixirs in the universe of compounds to make new medicines accessible.

Early stage investments

YUNGANG HUANG

RUNZE CHEN

Bota

Early stage investments

YUNGANG HUANG

RUNZE CHEN

XUFENG LI

SIBIONICS
SiBionics is a MedTech startup specialized in the R&D and commercialization of active implantable medical devices and medical artificial intelligence. Our company is headquartered in Shenzhen with additional R&D center and offices located in Los Angeles, Beijing and Guangzhou.

Our project pipeline includes Retinal Prosthesis, Continuous Glucose Monitoring, Diabetic Retinopathy Screening and Gastric Cancer Screening, covering major aspects of healthcare, from health and chronic conditions management, to disease screening, diagnostics and treatment.

Growth stage investments

YUNGANG HUANG

RUNZE CHEN

XUFENG LI

NUTSHELL
Today, it is increasingly recognized that more and more unmet medical needs may be met by tackling the undruggable targets in the realm of drug discovery. Along with other novel approaches, allostery has shown its potential to open another window for drug developers to broaden and diversify the drug space. Allostery is an inherent property of biomacromolecules in which topographically distinct binding sites within a protein are functionally coupled. Allosteric modulation of proteins enables exquisite control over a number of biological processes, presenting itself as a unique solution for drug developers to aim at undruggable targets. Furthermore, recent allosteric drugs, both approved and those still in clinical development stages, have simply demonstrated allostery as a proven drug discovery approach. NUTSEHLL is a suite of AI-based tools built upon a deep understanding of allosteric mechanism since 2013, when the enriched allosteric database was established around 2009. Currently, this well-established technology platform, in particular, the work flow know-how(SMA,PMA and PPA)enable to implement a complete compound discovery process from identification of the potential allosteric site, and all the way through to hit and lead molecule discovery, in conjunction with a strong medicinal chemistry capability. Thus far, NUTSHELL has been generating its own pipeline as well as enabling other academic and industry collaborators to develop allosteric drug. With our NUTSHELL proprietary platform and its early stage yet fast evolving allosteric based pipelines, NUTSHELL biotech is now becoming an oncology focused and novel target centered company and pioneering in allosteric drug discovery.

Early stage investments

YUNGANG HUANG